Trial Profile
A Randomized, Double Blind, Chronic Dosing (14 Days), Three Period, Placebo Controlled, Cross Over, Multi Center Study to Assess Efficacy and Safety of Two Dose Levels of AZD2115 MDI in Subjects With Moderate to Severe COPD
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Sep 2020
Price :
$35
*
At a glance
- Drugs AZD 2115 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Pearl Therapeutics
- 16 Oct 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 09 Jul 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
- 29 May 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.